GLP-1 RAs in Patients With Polycystic Ovary Syndrome (PCOS)
- Status
- CompletedResults none
- Why it is watched
- non-weight indication: endocrine, other_emerging
- Who it enrolls
- age 18 Years to 45 Years; female; BMI ≥24 required; non-obese participants included; conditions: Polycystic Ovary Syndrome
- Interventions
- GLP-1 RAs; calorie restricted diet
- Conditions
- Polycystic Ovary Syndrome
- Phase and size
- Phase 4 · 68 participants
- Dates
- Start 2021-05-15
Primary completion 2022-04-30 - Sponsor
- Shanghai 10th People's Hospital (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- the change in visceral adipose tissueuntil achievement of the weight loss target,an average of 12 weeks
02Eligibility
Who can take part
Inclusion Criteria: * Female aged 18- 45; * Meet 2003 Rotterdam criteria; * overweight/obesity,BMI≥24kg/m2. Exclusion Criteria: * any contraindication to dulaglutide (known or suspected hypersensitivity to dulaglutide or related products, previous acute pancreatitis or chronic pancreatitis, inflammatory bowel disease; personal history or family history of medullary thyroid carcinoma, or personal history of multiple endocrine neoplasia type 2)； * treatment with any other drugs that may interfere with the trial, including traditional Chinese medicine, contraceptives, metformin, GLP-1RA or pioglitazone within the last 3 months； * chronic kidney disease or severe liver dysfunction； * malignant tumors； * mental illness; * pregnancy or lactation； * inflammatory bowel disease; * recent participation in other weight-loss research projects within the last 3 months.
03Change log
Registry changes
No changes recorded since the trial was added.